TGF-Beta: a Master Switch in Tumor Immunity
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
The capacity of the immune system to distinguish foreign from self-antigen, and to subsequently eliminate the threat of disease without injuring the host is crucial for survival. It also serves to defend against tumor formation and progression via a process termed cancer immunosurveillance. Innate and adaptive immune cell types and effector molecules collectively function as extrinsic tumorsuppressor mechanisms. However, tumors may escape immunesurveillance through a variety of mechanisms that create a local microenvironment that is unfavorable for effective tumor immunity. Transforming growth factor β (TGF-β) has pleiotropic effects on the immune system, and is recognized as one of the most potent immunosuppressive agents in facilitating oncogenesis. The TGF-β pathway promotes cancer progression by concomitantly enhancing tumor metastases while inhibiting the protective host immunity. In this review, we discuss mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TGFβ is a key suppressive cytokine normally produced by immune cells but which can be co-opted by tumors to suppress effective immune responses (Batlle and Massagué, 2019; Gigante et al., 2012).”
From Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies (2020) · cites this paper as Gigante et al., 2012
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 2×
“2010; 184: 6556 [114] Bettelli E, Carrier Y, Gao W, et al.”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 2×
“Th17 cells produce IL-17, which is a potent inflammatory cytokine that impacts a variety of cell types including fibroblasts, endothelial cells, and epithelial cells to induce the expression of additional inflammatory cytokines, such as IL-6, TNF, G-CSF, chemokines, and matrix metalloproteases, all of which coordinate…”
BackgroundFunctions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943 · cited 2×
“Natural killer (NK) cells represent a small proportion (10-15%) of peripheral blood lymphocytes with dense intracellular cytolytic granules [31,32] and do not express antigen-specific (clonotypic) cell surface receptors, as in the cases of T and B cells.”
BackgroundVeldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 2×
“[110] Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B.”
BackgroundTumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
Zhou, L., Ivanov, I. I., Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E., Leonard, W. J., & Littman, D. R. (2007) · Nature Immunology · doi:10.1038/ni1488 · Cited by 2,141
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function
Zhou, L., Lopes, J. E., Chong, M. M. W., Ivanov, I. I., Min, R., Victora, G. D., Shen, Y., Du, J., Rubtsov, Y. P., Rudensky, A. Y., et al. (2008) · Nature · doi:10.1038/nature06878 · Cited by 1,863
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656 · cited 2×
“[32] Lanier LL.”
BackgroundTH-17 cells in the circle of immunity and autoimmunity
Bettelli, E., Oukka, M., & Kuchroo, V. K. (2007) · Nature Immunology · doi:10.1038/ni0407-345 · Cited by 1,517
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
Toll-like receptors control activation of adaptive immune responses
Schnare, M., Barton, G. M., Holt, A. C., Takeda, K., Akira, S., & Medzhitov, R. (2001) · Nature Immunology · doi:10.1038/ni712 · Cited by 1,365
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 2×
“[58] Steidl C, Lee T, Shah SP, et al.”
BackgroundMacrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241 · cited 3×
“Macrophages activated towards a classical, proinflammatory phenotype (M1) elicit anti-tumor activity and promote TH1 immune responses, while macrophages exhibiting an alternative phenotype (M2) promote biased TH2 immune responses and tissue remodelling [61].”
BackgroundInfluentialInducing and expanding regulatory T cell populations by foreign antigen
Kretschmer, K., Apostolou, I., Hawiger, D., Khazaie, K., Nussenzweig, M. C., & von Boehmer, H. (2005) · Nature Immunology · doi:10.1038/ni1265 · Cited by 1,241
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Fantini, M. C., Becker, C., Monteleone, G., Pallone, F., Galle, P. R., & Neurath, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5149 · Cited by 1,135
Lymphocyte-Mediated Cytotoxicity
Russell, J. H., & Ley, T. J. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100201.131730 · Cited by 1,122
Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor?
Curotto de Lafaille, M. A., & Lafaille, J. J. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.002 · Cited by 1,055
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 962
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · cited 2×
“The presence of these tumor-infiltrating cells coincides with TGF- secretion, making them suspected producers of TGF- 1 which accumulates at the invasion front of the tumor [25].”
BackgroundQuezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · cited 2×
“[96] Quezada SA, Simpson TR, Peggs KS, et al.”
BackgroundRegulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.-R., Zhang, Y., & Wrana, J. L. (2005) · Science · doi:10.1126/science.1105718 · Cited by 881
Macrophage activation switching: an asset for the resolution of inflammation
Porcheray, F., Viaud, S., Rimaniol, A.-C., Léone, C., Samah, B., Dereuddre-Bosquet, N., Dormont, D., & Gras, G. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02934.x · Cited by 840 · cited 2×
“[64] Porcheray F, Viaud S, Rimaniol AC, et al.”
BackgroundBurchill, M. A., Yang, J., Vogtenhuber, C., Blazar, B. R., & Farrar, M. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.280 · Cited by 834
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer
Tone, Y., Furuuchi, K., Kojima, Y., Tykocinski, M. L., Greene, M. I., & Tone, M. (2008) · Nature Immunology · doi:10.1038/ni1549 · Cited by 807 · cited 2×
“[119] Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone”
BackgroundLi, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 805
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 763
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682 · cited 2×
“[30] Waldhauer I, Steinle A.”
BackgroundSerafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Induction of myeloid‐derived suppressor cells by tumor exosomes
Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z., Wang, J., Cheng, Z., Shah, S. V., Wang, G., Zhang, L., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24249 · Cited by 598
IL-17: prototype member of an emerging cytokine family
Aggarwal, S., & Gurney, A. L. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.1.1 · Cited by 597
Close encounters of different kinds: Dendritic cells and NK cells take centre stage
Degli-Esposti, M. A., & Smyth, M. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1549 · Cited by 554
Lee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 549
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation
Gorelik, L., Constant, S., & Flavell, R. A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012076 · Cited by 521
Tolerogenic dendritic cells: cytokine modulation comes of age
Rutella, S., Danese, S., & Leone, G. (2006) · Blood · doi:10.1182/blood-2006-03-006403 · Cited by 491
Differentiation of T Regulatory Cells by Immature Dendritic Cells
Roncarolo, M.-G., Levings, M. K., & Traversari, C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.f5 · Cited by 483
Marie, J. C., Liggitt, D., & Rudensky, A. Y. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.012 · Cited by 480 · cited 2×
“[92] Marie JC, Liggitt D, Rudensky AY.”
BackgroundBruna, A., Darken, R. S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.023 · Cited by 472
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Laouar, Y., Sutterwala, F. S., Gorelik, L., & Flavell, R. A. (2005) · Nature Immunology · doi:10.1038/ni1197 · Cited by 451
Latent Transforming Growth Factor-β (TGF-β) Binding Proteins: Orchestrators of TGF-β Availability
Rifkin, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r400029200 · Cited by 420
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A., & Zou, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6730 · Cited by 416
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380 · cited 2×
“[33] Fauriat C, Just-Landi S, Mallet F, et al.”
BackgroundIMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE
Burnet, F. M. (1967) · The Lancet · doi:10.1016/s0140-6736(67)92837-1 · Cited by 369
Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., & Era, S. (2005) · Oncology Reports · doi:10.3892/or.14.2.425 · Cited by 366
Patel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903143 · Cited by 363
Tumor-associated macrophages: Effectors of angiogenesis and tumor progression
Coffelt, S. B., Hughes, R., & Lewis, C. E. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.02.004 · Cited by 355
TGF- downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients
Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop009 · Cited by 322
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314
Self-citationCarlsten, M., Norell, H., Bryceson, Y. T., Poschke, I., Schedvins, K., Ljunggren, H.-G., Kiessling, R., & Malmberg, K.-J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283
Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancer
Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R.-F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710686105 · Cited by 279 · cited 2×
“[106] Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF.”
BackgroundTrotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
The promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage
Perrot, I., Blanchard, D., Freymond, N., Isaac, S., Guibert, B., Pachéco, Y., & Lebecque, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2763 · Cited by 266
The prevalence of Th17 cells in patients with gastric cancer
Zhang, B., Rong, G., Wei, H., Zhang, M., Bi, J., Ma, L., Xue, X., Wei, G., Liu, X., & Fang, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.060 · Cited by 257
Ojalvo, L. S., Whittaker, C. A., Condeelis, J. S., & Pollard, J. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902360 · Cited by 238
Ouyang, W., Beckett, O., Ma, Q., & Li, M. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.012 · Cited by 236
Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2264 · Cited by 234 · cited 2×
“Several studies have identified the reduced expression of these molecules and weakened NK cell activity in human cancer [33-35].”
BackgroundType 17 CD8+ T cells display enhanced antitumor immunity
Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L., Heemskerk, B., Wrzesinski, C., Borman, Z. A., Muranski, P., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-02-203935 · Cited by 225
Xie, W. Q., Mertens, J. C., Reiss, D. J., Rimm, D. L., Camp, R. L., Haffty, B. G., & Reiß, M. (2002) · PubMed · Cited by 217
Loke, P., MacDonald, A. S., Robb, A., Maizels, R. M., & Allen, J. E. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9<2669::aid-immu2669>3.0.co;2-1 · Cited by 211
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
Heath, V. L., Murphy, E. E., Crain, C., Tomlinson, M. G., & O’Garra, A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9<2639::aid-immu2639>3.0.co;2-7 · Cited by 193
Sanjabi, S., Mosaheb, M. M., & Flavell, R. A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.020 · Cited by 190
Ilkovitch, D., & Lopez, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4625 · Cited by 188
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9002-6 · Cited by 183
Wilson, E. B., El-Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 174
Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T., & Gregory, C. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0712671 · Cited by 171
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
Coe, D., Begom, S., Addey, C., White, M., Dyson, J., & Chai, J.-G. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0866-5 · Cited by 168
Baxevanis, C. N., Voutsas, I. F., Tsitsilonis, O. E., Gritzapis, A. D., Sotiriadou, R., & Papamichail, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3902 · Cited by 160
Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Yang, L., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2556 · Cited by 151 · cited 2×
“[20] Yang L, Moses HL.”
BackgroundReversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Wojtowicz‐Praga, S. (2003) · Investigational New Drugs · doi:10.1023/a:1022951824806 · Cited by 146
Tumor-Derived TGFβ-1 Induces Dendritic Cell Apoptosis in the Sentinel Lymph Node
Ito, M., Minamiya, Y., Kawai, H., Saito, S., Saito, H., Nakagawa, T., Imai, K., Hirokawa, M., & Ogawa, J.-I. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5637 · Cited by 141
Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response
Fujita, S., Seino, K.-I., Sato, K., Sato, Y., Eizumi, K., Yamashita, N., Taniguchi, M., & Sato, K. (2006) · Blood · doi:10.1182/blood-2005-10-4190 · Cited by 136
Anergic T cells act as suppressor cellsin vitro andin vivo
Chai, J.-G., Bartok, I., Chandler, P., Vendetti, S., Antoniou, A., Dyson, J., & Lechler, R. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<686::aid-immu686>3.0.co;2-n · Cited by 134
Gnerlich, J. L., Mitchem, J. B., Weir, J. S., Sankpal, N. V., Kashiwagi, H., Belt, B. A., Porembka, M. R., Herndon, J. M., Eberlein, T. J., Goedegebuure, P., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902609 · Cited by 133
T Helper 1 Cytokine mRNA Is Increased in Spontaneously Regressing Primary Melanomas
Lowes, M. A., Bishop, G. A., Crotty, K. A., Barnetson, R. S. C., & Halliday, G. M. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12292705 · Cited by 122
Tumor-Derived TGF-β Reduces the Efficacy of Dendritic Cell/Tumor Fusion Vaccine
Kao, J. Y., Gong, Y., Chen, C.-M., Zheng, Q.-D., & Chen, J.-J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3806 · Cited by 118
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells
Donkor, M. K., Lahue, E. E., Hoke, T. A., Shafer, L. R., Çoşkun, U., Solheim, J. C., Gülen, D., Bishay, J., & Talmadge, J. E. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.021 · Cited by 106
Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer.
Seya, T., Akazawa, T., Uehori, J., Matsumoto, M., Azuma, I., & Toyoshima, K. (2003) · PubMed · Cited by 106
Zorn, E., & Hercend, T. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<592::aid-immu592>3.0.co;2-2 · Cited by 101
Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells
Stoitzner, P., Green, L. K., Jung, J. Y., Price, K. M., Atarea, H., Kivell, B. M., & Ronchese, F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0487-4 · Cited by 96
Gu, A.-D., Wang, Y., Lin, L., Zhang, S. S., & Wan, Y. Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108352109 · Cited by 92
Keski‐Oja, J., Koli, K. M., & von Melchner, H. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.10.003 · Cited by 92
Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo
Radoja, S., Rao, T. D., Hillman, D., & Frey, A. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2619 · Cited by 88
Kottke, T. J., Sanchez-Perez, L. A., Díaz, R. M., Thompson, J., Chong, H., Harrington, K. J., Calderwood, S. K., Pulido, J. S., Georgopoulos, N. T., Selby, P. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2259 · Cited by 87
Byrne, S. N., Knox, M. C., & Halliday, G. M. (2008) · Immunology & Cell Biology · doi:10.1038/sj.icb.7100116 · Cited by 62
Gigante, M., Mandić, M., Wesa, A. K., Cavalcanti, E., DAMBROSIO, M., Mancini, V., Battaglia, M., Gesualdo, L., Storkus, W. J., & Ranieri, E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318167b023 · Cited by 49
Self-citationGigante, M., Blasi, A., Loverre, A., Mancini, V., Battaglia, M., Selvaggi, F. P., Maiorano, E., Napoli, A., Castellano, G., Storkus, W. J., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.015 · Cited by 48
Self-citationWang, L., Wen, W., Yuan, J., Helfand, B., Li, Y., Shi, C., Tian, F., Zheng, J., Wang, F., Chen, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1758 · Cited by 43
Dendritic Cells in Tumor Immunology and Immunotherapy
Turtle, C. J., & Hart, D. N. J. (2004) · Current Drug Targets · doi:10.2174/1389450043490640 · Cited by 34
Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.
Kershaw, M. H., Trapani, J. A., & Smyth, M. J. (1995) · PubMed · Cited by 26
Translational Mini-Review Series on Vaccines: Dendritic cell-based vaccines in renal cancer
Ranieri, E., Gigante, M., Storkus, W. J., & Gesualdo, L. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03305.x · Cited by 16
Self-citationKawai, K., Saijo, K., Oikawa, T., Ohno, T., & Akaza, H. (2004) · International Journal of Urology · doi:10.1111/j.1442-2042.2004.00954.x · Cited by 11
Cited by
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Poniatowski, Ł. A., Wojdasiewicz, P., Gasik, R., & Szukiewicz, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/137823 · Cited by 281
Krstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Zhong, X., Zhang, H.-T., Zhu, Y., Liang, Y., Yuan, Z., Li, J., Li, X., Li, X., Jia, Y., Tian, H., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1141-9 · Cited by 144
Metadata
- Authors
- Gigante, M., Gesualdo, L., & Ranieri, E.
- Affiliations
- University of Foggia (IT)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 18
- Issue
- 27
- Pages
- 4126-4134
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2055370220
- Cited by
- 45
- References
- 121
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 5
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TGF-beta, antitumor immunity, tumor surveillance, immunosuppression, tumor microenvironment, metastasis, cancer immunotherapy, immune evasion, carcinogenesis
- MeSH terms
- Animals, Humans, Immunity, Innate, Immunologic Surveillance, Neoplasm Metastasis, Neoplasms, Transforming Growth Factor beta, Disease Progression, Adaptive Immunity, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.